Electromed (ELMD) Stock Analysis & AI Equity Report
Electromed (ELMD) overview
Electromed (ELMD) stock analysis and AI equity research. For financial year 2026, Valuatum's model shows revenue of USD 73.8m and operating profit of USD 13.9m; the year-end share price was 42.30 USD and market capitalisation was USD 354m. Electromed is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Electromed's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Electromed
Electromed develops, manufactures, markets, and sells airway clearance products, including the SmartVest Airway Clearance System for patients with compromised pulmonary function. The system uses a programmable air pulse generator and therapy garment to provide high-frequency chest wall oscillation treatment. Electromed sells to home health care and acute care settings, serving patients through referrals from clinicians and sales to hospitals and clinics.
Generate the Electromed report
Electromed is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Electromed and represent financial year 2026. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Electromed
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.